Skip links

Main navigation

Editas (NASDAQ:EDIT) completed their IPO this week in a difficult market and is now the first "pure play" on CRISPR. In the biotechnology field…

As we start 2016 it's a good time to review and update all our positions in the folio. We're eliminating quite a few and…

“Hi! I’m dating stock called MTCH looking for a committed relationship with investors. I’ve got a ton of baggage from prior acquisitions and my latest…

Mimecast (Nasdaq: MIME) is a SaaS/Cloud company focused on enterprise email security and archiving. The story is a little mixed up though. The company…

3 days ago by Candyman

Editas (NASDAQ:EDIT) completed their IPO this week in a difficult market and is now the first "pure play" on CRISPR. In the biotechnology field CRISPR is viewed as the Next Big Thing. Journals like the MIT Technology Review have called…

3 weeks ago by Candyman

As we start 2016 it's a good time to review and update all our positions in the folio. We're eliminating quite a few and adding some new names. Generally we are hanging on to many of our best performers.

First…
3 months ago by Candyman

“Hi! I’m dating stock called MTCH looking for a committed relationship with investors. I’ve got a ton of baggage from prior acquisitions and my latest passion is taking me in a new direction which I don’t have a handle on yet.…

3 months ago by Candyman

Mimecast (Nasdaq: MIME) is a SaaS/Cloud company focused on enterprise email security and archiving. The story is a little mixed up though. The company focuses on email but is positioned (at least by Gartner Group) as an information archiving company.…

3 months ago by Candyman

Square (NYSE: SQ) is coming public as a $1B revenue company with quite a few moving parts.
There's the negative margin Starbucks business which is going away, plus the "ratchet" provision whereby prior investors will have their number of…

3 months ago by Candyman

Xtera (NASDAQ: XCOM) provides long-range high-capacity optical networking systems. Company claims that they are unique because they simultaneously offer very high speed *and* long distance solutions. In the past most customers wanted one or the other - now everyone wants…

3 months ago by Candyman

GenSight (NASDAQ: GNST)  is smaller size biotech deal with Leerick, Evercore and Canaccord on the cover. The 4.6M shares are all primary with a $14 mid-point. It's scheduled for tonight, November 5th. Post-IPO there will be close to 19M shares with a market capitalization…

4 months ago by Candyman

Adesto (NASDAQ: IOTS) doesn't look like much on the surface - flat revenues, consistent losses in a heavily commoditized business - computer memory. So it's not surprising that they just reduced their proposed price to $7/share with their tier-2 underwriting…

4 months ago by Candyman

[UPDATE: The deal is "multiple times oversubscribed" so it'll be a winner off the finish line. I also like this post by an NYU professor on the company and the deal. It's on a new platform called Harvest (HVST) which…

4 months ago by Candyman

The recent news for Verastem (Nasdaq:VSTM) has been terrible. Yesterday they announced a layoff of 50% of their workforce which will get the company down to 20 people and save $4.9M a year in operating costs. They still have $132M in…

4 months ago by Candyman

Pure Storage [NYSE:PSTG] priced at $17,  above their proposed price range $14-16 price range. It's clear they have a great story and management team with revenue growth numbers that speak volumes, at scale. After doing $6M in 2013 we see them…

4 months ago by Candyman

At first Aclaris [Nasdaq: ACRS] didn't catch my eye. The phrase "concentrated hydrogen peroxide" sounded too simple to offer any sustainable competitive advantage.

However a favorable mention from the famous "Dr. KSS" who…

4 months ago by Candyman

There's a big gap between the PayPal (PYPL) story/investor slide deck and market reality. As an investor we like it - hits all the right notes and management has all the right answers. But as a user we scratch our…

4 months ago by Candyman

Despite a dicey market we are staring down a full calendar this week and next. There are 13 deals in active marketing now which is pretty good (the system peaks out at around 20 or so because things are still manual,…

5 months ago by Candyman

We were impressed by the Penumbra (NYSE:PEN) neuro and vascular technologies demonstrated in their roadshow. Combined with their meaningful revenue ($125M in 2014 which was up 41%) and profitability this is an IPO to watch and probably own. Being able…

5 months ago by Candyman
Wayfair Under Attack

The shorts have come out in force on Wayfair (NYSE:W) and their attacks are blistering (PDF). The shares have held up well so far, in part due to sell-side analysts at large firms…

5 months ago by Candyman

It's been a volatile August and the world continues to change, sometimes it feels like it's doing so at a faster pace!

That means it's a good time to update the IPO Candy Folio which to remind you is…

5 months ago by Candyman

Ambarella (AMBA) has been a white-hot IPO since coming out in 2012 it's up over 1400%! The company is the current king of video-processing chips. More elaborately stated in their company description: "The company’s system-on-a-chip designs integrated HD video processing,…

5 months ago by Candyman
The Amplify Snack Brands Story

Amplify Snack Brands (NYSE:BETR) came public in early August at $18/share but traded down from the start to reach the current $13-14 level. The company is generating very attractive margins from their flagship…

6 months ago by Candyman

Planet Fitness [NYSE:PLNT] is a lightning rod for controversy and opinions. Serious fitness types tend to hate PLNT and even take the time to produce videos highlighting how inferior Planet Fitness gyms are, how wrong their policies against excessive lifting…

6 months ago by Candyman

We published a note on Malibu Boats (NASDAQ:MBUU) back in January and didn't love the IPO. In short it seemed fully valued at the proposed IPO price. The IPO was a success and the shares have traded up to…

7 months ago by Candyman

Ooma (NASDAQ: OOMA) is another alternative communications company that provides cloud-based phone services to consumers and small businesses. The company is like some other small public companies like Vonage (NYSE:VG), MagicJack (NASDAQ: CALL), and RingCentral (NYSE: RNG).

Ooma has an…

8 months ago by Candyman

It's no surprise that the "uber for doctors" had a hit IPO - pricing above-the-range at $19 and opening at $29.

Our IV estimate of $11 is far less exciting though. Why so low? The model itself is below…

8 months ago by Candyman

As we exit June and head into the summer we made a number of adjustments to our IPO Candy Folio. We're also providing a link to a sheet where you can see the holdings if you're interested. This isn't…

8 months ago by Candyman

The size and price range have already been increased for Glaukos (GKOS), a medical technology company that plans to price their IPO on Wednesday. Their device is so small it defies imagination but is a proven treatment for glaucoma. 

Three…

8 months ago by Candyman

MINDBODY (NASDAQ: MB) completed their IPO last week at $14, had a brief pop at the open to $15 and promptly traded down to $12.

What gives? Isn't this the "OpenTable (PCLN) of the health and fitness industry" as…

8 months ago by Candyman

UPDATE: The deal priced at $20 and traded to $30. There have been some other dissenting voices like this one from Tim Mullany at MarketWatch. He's a little…

8 months ago by Candyman

Chicken is a versatile food. We can enjoy flame grilled at El Pollo Loco (LOCO), fried at KFC (YUM), Popeye's (PLKI), at bars like Buffalo Wild Wings (BWLD) and even with scantily-clad waitresses at Hooters (HOTR).

Wingstop (WING) is…

9 months ago by Candyman

The $75M David's Tea (DTEA) IPO is being offered by Goldman and JP Morgan. The market capitalization at the $15-midpoint would be $350M. Expected pricing is Thursday night for trading on Friday. If things go like they did for…

9 months ago by Candyman

One of the "hot deals" on offer this week is Bojangles' (NASDAQ: BOJA) with their "Famous Chicken and Biscuits." We've had a steady stream of new restaurant deals in the past few years with names including Shake Shack (SHAK), Chuy's…

10 months ago by Candyman
From Moodcatz via Etsy

Etsy has come a long way since the early days when many of us were laughing to the point of tears with posts from the infamous and now-defunct Regretsy.com. There are still funny things to…

11 months ago by Candyman

Summary: SolarEdge gets good marks for the banking team, company positioning and business strength but their market opportunity and technology advantages are less compelling given the proposed valuation of 2x the current revenue run rate. For example primary competitor Enphase…

12 months ago by Candyman

There's a lot changing in retail and our initial impressions of Maxpoint (MXPT) suggest this is one company that is likely to succeed as one of the new retail technologies that can effectively bridge the gap between online advertising and…

1 year ago by Candyman

We're as fascinated by genomics and "personalized medicine" as the next guy. Even Obama has the bug and touted the "Precision Medicine Initiative." Genetic testing even made it into pop science in 2007 when Google invested nearly $4M in

1 year ago by Candyman

Today we made a few changes to the IPO Candy Folio to close out the first month of the year. Two deals we like priced today - Shake Shack and Spark Therapeutics…

1 year ago by Candyman

This deal caught our eye (sorry!) in part because we're at the age where reading glasses are sometimes helpful - small print, low light. Put simply Presbia (NASDAQ: LENS) makes a small microlens which is then inserted into a small "pocket" added…

1 year ago by Candyman

As we wrap up the month and the year we made some adjustments today (December 15th) to the IPO Candy Folio of stocks. For more information see our IPO Candy Investment page.

New…
1 year ago by Candyman

LendingClub (LC) is one of the most anticipated public offerings of the year and is expected to price Wednesday night to trade on Thursday. They just raised the range to $12-14 from the prior $10-12. The market is acting poorly…

1 year ago by Candyman

In the spirit of full disclosure from 1995 to 2004 I was an equity analyst, research manager and director of equity research at two different “boutique” brokers. My experience there, particularly with the last one at Adams Harkness in Boston…

1 year ago by Candyman

Histogenics (HSGX) may finally deliver an engineered cartilage that can make damaged knees good again. There are a range of new alternatives being developed but the positioning of Histogenics and their “NeoCart” is encouraging. They are enrolling patients for a…

We love IPOs

The IPO market provides a magical window into the most exciting technologies, emerging consumer trends and important business developments - all testing their mettle in the crucible of the public markets. We are constantly learning and researching to deliver the best insights available.

We are independent

We have no vested interests driving our work. All the investment banks and brokers on a deal are paid to do a sales and marketing job. Our job is to remain objective and use a fact-based approach to evaluate the potential for an IPO.

We get the best ratings

IPO Candy has been recognized since 2009 as the single best place to get commentary, analysis and assets in the IPO market. The most common write-in comment we get from users is that they "love what we do."

We share everything we know

With three decades of research under our belt we want to share what we have learned and the best practices we have discovered. Our IPO University contains texts, videos and resources to share our process and help everyone develop their skills.

IPO Candy

Sweet 326
1313 Washington Street
Boston, MA 02118

IPO Candy on Twitter

Subscribe to our newsletter